Clinical Trial Detail

NCT ID NCT02677116
Title A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Eli Lilly and Company
Indications

Advanced Solid Tumor

central nervous system cancer

Therapies

Doxorubicin

Ifosfamide

Irinotecan + Vincristine Sulfate

Olaratumab

Age Groups: child

No variant requirements are available.